News

Mar 05, 2020

Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection

Jan 19, 2020

Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R

Nov 13, 2019

Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.

Feb 21, 2019

Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019

Nov 09, 2018

Zhimeng Biopharma presented the discovery and efficacy data of its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco

prev
1
2
next

Get in touch

Contact Us About Us Leadership Team Scientific Advisors